Related Experiment Video

Updated: May 24, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.4K

Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy

Pankaj Garg1, Sravani Ramisetty2, Meera Nair3

  • 1Department of Chemistry, GLA University, Mathura, Uttar Pradesh 281406, India.

Biochemical Pharmacology
|March 6, 2025
PubMed

Insights

Targeting the PI3K/AKT/mTOR pathway is crucial for advanced breast cancer (BC) treatment. This review details pathway dysregulation, current inhibitors, and future strategies like immunotherapy for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer (BC) impacts millions globally, necessitating advanced therapeutic strategies.
  • The PI3K/AKT/mTOR pathway is integral to BC progression, influencing tumor growth, survival, and treatment resistance.
  • Dysregulation of this pathway is a significant factor in BC development and therapeutic challenges.

Purpose of the Study:

  • To review the dysregulation mechanisms of the PI3K/AKT/mTOR pathway in breast cancer.
  • To summarize current therapeutic strategies targeting this pathway, including inhibitors and combination therapies.
  • To explore future directions in BC treatment, focusing on next-generation inhibitors, personalized medicine, and immunotherapy integration.

Main Methods:

  • Comprehensive literature review of studies on PI3K/AKT/mTOR pathway in breast cancer.
  • Analysis of genetic alterations (e.g., PIK3CA mutations, PTEN loss) leading to pathway dysregulation.
  • Evaluation of current and emerging therapeutic interventions targeting the pathway.

Main Results:

  • PI3K/AKT/mTOR pathway dysregulation, driven by genetic mutations like PIK3CA and PTEN loss, is a key feature of breast cancer.
  • Targeted inhibitors (PI3K, AKT, mTOR) and combination therapies show promise in overcoming resistance and enhancing treatment efficacy.
  • Biomarker-guided personalized treatment plans and immunotherapy integration represent promising future therapeutic avenues.

Conclusions:

  • Targeting the PI3K/AKT/mTOR pathway offers significant potential for improving breast cancer treatment outcomes.
  • Future research should focus on developing novel inhibitors, personalized approaches, and combination strategies including immunotherapy.
  • Enhanced understanding and therapeutic targeting of this pathway are critical for improving patient survival and quality of life in breast cancer.
Keywords:
Breast cancerDrug-resistance mechanismsPI3K/AKT/mTOR pathwayPIK3CA mutationsPTEN lossPathway inhibitors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K